1. Analyst View
2. Research Overview
3. Industry Overview
3.1 Worldwide Therapeutic Segmentation in the Pharmaceutical Market
3.2 Worldwide Pharmaceutical Market Segmentation by Region
3.3 Worldwide Expenditure on Pharmaceutical Drugs
3.4 Worldwide Emerging Markets in Pharmaceutical Industry
4. Industry Performance
4.1 By Vendors
4.2 By Therapy Classes and Products
4.2.1 Therapy Classes
4.2.2 Product Classes
4.2.2.1 Biologics Market
4.2.2.2 Block Buster Products
4.2.2.3 Over the Counter Products (OTC)
4.3 By Geographical Spread
4.3.1 Asia-Pacific
4.3.1.1 India
4.3.1.2 China
4.3.1.3 Australia
4.3.1.4 Japan
4.3.1.5 Indonesia
4.3.1.6 Hong Kong
4.3.1.7 South Korea
4.3.2 Europe
4.3.2.1 United Kingdom
4.3.2.2 France
4.3.2.3 Germany
4.3.3 Latin America
4.3.3.1 Mexico
4.3.3.2 Brazil
4.3.3.3 Chile
4.3.4 North America
4.3.4.1 United States of America
4.3.4.2 Canada
4.3.5 Africa
4.3.5.1 South Africa
4.3.5.2 Egypt
4.3.5.3 Saudi Arabia
5. Key Driving Forces
6. Opportunities and Challenges
7. Future Outlook, 2010
8. Key Players
8.1 GlaxoSmithKline
8.2 AstraZeneca
8.3 Johnson & Johnson
8.4 Roche
8.5 Merck & Co.
8.6 Novartis
8.7 Wyeth
8.8 Bristol-Myers Squibb
8.9 Ranbaxy Laboratories Ltd.

List of Figures:

Figure 3-1: Worldwide - Pharmaceutical Market Revenue (in Billion US$), 2001-2005
Figure 3-2: Worldwide - Pharmaceutical Market by Therapeutic Segmentation (%), 2004
Figure 3-3: Worldwide - Pharmaceutical Market Segment by Region (%), 2004
Figure 3-4: Worldwide - Annual Pharmaceutical Expenditure/Head by Country (in US$), 2003
Figure 4-1: Worldwide - Growth in Biologics Market (in Billion US$), 2004 & 2005
Figure 4-2: Worldwide - Over the Counter Products Sales (in Billion US$), 2001-2005
Figure 4-3: India - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-4: China - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-5: China - Population Aged above 65 Years (%), 2006-2011
Figure 4-6: China - GDP Growth (in Trillion US$), 2001-2011E
Figure 4-7: Australia - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-8: Australia - Pharmaceutical Expenditure by Government (in Billion Aus$), 2001-2003
Figure 4-9: Japan - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-10: Indonesia - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-11: Hong Kong - Pharmaceutical Sales Market (in Million US$), 2000-2005
Figure 4-12: South Korea - Pharmaceutical Market Revenue (in Billion US$), 2001-2005
Figure 4-13: United Kingdom - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-14: France - Generic Drugs Sale (in Million US$), 2000-2004
Figure 4-15: France - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-16: Germany - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-17: Germany - Increase in Life Expectancy (in Year), 2006-2010
Figure 4-18: Germany - Forecast of Pharmaceutical Sales (in Billion US$), 2006-2010
Figure 4-19: Mexico - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-20: Brazil - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-21: Chile - Pharmaceutical Sales Market (in Million US$), 2001-2005
Figure 4-22: USA - Pharmaceutical Sales Market (in Billion US$), 2001-2005
Figure 4-23: USA - Forecast of Clinical Trial Business (in Billion US$), 2006-2011
Figure 4-24: Canada - Pharmaceutical Sales Market (in Billion US$), 2000-2005
Figure 4-25: South Africa - Pharmaceutical Market Revenue (in Billion US$), 2001-2005
Figure 5-1: Worldwide - Average Life Expectancy (in Year), 2001-2005
Figure 5-2: Worldwide - Annual Spending in Healthcare (in US$/Head), 2001-2005
Figure 5-3: Worldwide - Number of Block Buster Drugs (2000 & 2005)
Figure 5-4: Worldwide - Growth in Over the Counter Drugs Sale (in Billion US$), 2004 & 2005
Figure 6-1: Worldwide - Forecast of Clinical Trial Market (in Billion US$), 2006 & 2007
Figure 6-2: Worldwide - Forecast for Enzyme Inhibitor Market (in Billion US$), 2006-2011
Figure 6-3: Worldwide - Forecast for Plant Derived Drugs & Applications Market (in Billion US$), 2006-2011
Figure 6-4: Worldwide - Growth in Plant Derived Drugs Sale (in Billion US$), 2005, 2006 & 2011
Figure 6-5: Worldwide - Growth of Influenza Therapeutics Market (in Billion US$), 2006-2010
Figure 6-6: Worldwide - Growth of Pharmacogenomics Market (in Billion US$), 2006-2009
Figure 6-7: Worldwide - Growth of Contract Manufacturing (in Billion US$), 2006-2009
Figure 6-8: Worldwide - Anti-infective Market (in Billion US$), 2006-2010
Figure 7-1: Worldwide - Forecast of Pharmaceutical Market (in Billion US$), 2006-2010
Figure 7-2: Worldwide - Application Market for RFID Technology in Pharmaceutical Industry (in Billion US$), 2006-2011
Figure 8-1: GlaxoSmithKline - Stock Performance
Figure 8-2: AstraZeneca - Stock Performance
Figure 8-3: Johnson & Johnson - Stock Performance
Figure 8-4: Roche - Stock Performance
Figure 8-5: Merck & Co. - Stock Performance
Figure 8-6: Norvatis - Stock Performance
Figure 8-7: Wyeth - Stock Performance
Figure 8-8: Bristol-Myers Squibb - Stock Performance
Figure 8-9: Ranbaxy Laboratories Ltd. - Stock Performance

List of Tables:

Table 4-1: Worldwide - Pharmaceutical Sales by Top 10 Vendors (in Billion US$), 2005
Table 4-2: Worldwide - Pharmaceutical Sales by Major Therapy Classes (in Billion US$), 2005
Table 4-3: Worldwide - Pharmaceutical Sales by Leading Product Category (in Billion US$), 2005
Table 4-4: Worldwide - Over the Counter Drugs Sale by Therapy Classes (in Billion US$), 2005
Table 4-5: Worldwide - Over the Counter Drugs Market by Company (in Billion US$), 2005
Table 8-1: GlaxoSmithKline - Key Financial Overview (in Million US$), 2001-2005
Table 8-2: AstraZeneca - Key Financial Overview (in Million US$), 2005 & 2006
Table 8-3: Johnson & Johnson - Key Financial Overview (in Million US$), 2003-2005
Table 8-4: Roche - Key Financial Overview (in Million US$), 2005
Table 8-5: Merck & Co. - Key Financial Overview (in Million US$), 2003-2005
Table 8-6: Novartis - Key Financial Overview (in Million US$), 2001-2005
Table 8-7: Wyeth - Key Financial Overview (in Million US$), 2001-2005
Table 8-8: Bristol-Myers Squibb - Key Financial Overview (in Million US$), 2001-2005
Table 8-9: Ranbaxy Laboratories Ltd. - Key Financial Overview (in Million US$), 2002-2004